Edition:
United States

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

23.89USD
29 Sep 2016
Change (% chg)

-- (--)
Prev Close
$23.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
377,857
52-wk High
$25.47
52-wk Low
$12.25

DEPO.OQ

Chart for DEPO.OQ

About

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company's products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment,... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $1,466.04
Shares Outstanding(Mil.): 61.37
Dividend: --
Yield (%): --

Financials

  DEPO.OQ Industry Sector
P/E (TTM): -- 37.66 37.54
EPS (TTM): -1.22 -- --
ROI: -6.67 14.54 13.98
ROE: -22.98 15.32 14.88

Starboard sets date for special meeting of Depomed shareholders

Activist investor Starboard Value LP, which owns 9.8 percent of drugmaker Depomed Inc and wants to oust the company's board, said on Monday it had won enough support from shareholders to set Nov. 15 as the date for a special meeting.

Sep 19 2016

BRIEF-Starboard delivers special meeting request to Depomed and issues letter to Depomed shareholders

* Delivers special meeting request to Depomed and issues letter to Depomed shareholders

Sep 19 2016

Starboard sets date for special meeting of Depomed shareholders

Sept 19 Activist investor Starboard Value LP, which owns 9.8 percent of drugmaker Depomed Inc and wants to oust the company's board, said on Monday it had won enough support from shareholders to set Nov. 15 as the date for a special meeting.

Sep 19 2016

BRIEF-Depomed receives request to call special meeting of shareholders

* Starboard Value Lp has delivered to Depomed a written request calling for a special meeting of depomed shareholders to be held on Tuesday, Nov 15, 2016.

Sep 16 2016

Drugmaker Depomed prepares to explore a sale -sources

Drug maker Depomed Inc is preparing to put itself up for sale, following calls from activist investor Starboard Value LP to explore such a move, just a year after it fought off a hostile acquisition bid, people familiar with the matter said.

Sep 15 2016

Exclusive: Drugmaker Depomed prepares to explore a sale - sources

Drug maker Depomed Inc is preparing to put itself up for sale, following calls from activist investor Starboard Value LP to explore such a move, just a year after it fought off a hostile acquisition bid, people familiar with the matter said.

Sep 15 2016

RPT-UPDATE 2-Horizon Pharma to buy Raptor Pharma for $800 mln

Sept 12 Horizon Pharma Plc said it would buy Raptor Pharmaceutical Corp for nearly $800 million to bolster its portfolio of drugs to treat rare diseases and reduce its dependence on the primary care market.

Sep 12 2016

Horizon Pharma to buy Raptor Pharma for $800 mln

Horizon Pharma Plc said it would buy Raptor Pharmaceutical Corp for nearly $800 million to bolster its portfolio of drugs to treat rare diseases and reduce its dependence on the primary care market.

Sep 12 2016

UPDATE 2-Horizon Pharma to buy Raptor Pharma for $800 mln

Sept 12 Horizon Pharma Plc said it would buy Raptor Pharmaceutical Corp for nearly $800 million to bolster its portfolio of drugs to treat rare diseases and reduce its dependence on the primary care market.

Sep 12 2016

BRIEF-Starboard delivers letter to Depomed shareholders

* Given ownership stake, and special meeting would only require one shareholder to consent, starboard to control timing of special meeting

Jul 26 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.